Search

Objective To identify the rate of catastrophizing in a cohort of subjects with chronic pain after self-reported mesh complications and identify interactions of catastrophization with other patient factors, such as age, number of pelvic surgeries, and intent to sue. Catastrophizing has been shown to be a risk factor for chronicity of pain, disability, and depression. Methods The pain catastrophization scale (PCS) identifies patients likely to have an exaggerated, negative thought process in response to pain. Subjects throughout the United States with self-described complications of vaginal mesh completed an internet-based, anonymous survey, featuring multiple standardized questionnaires including the PCS and female Genitourinary Pain Index (GUPI). A previously defined threshold score of >30 on the PCS defined high-pain catastrophizing. Statistical analysis was performed using χ² test and t test for categorical and continuous variables, respectively. Results Ninety of 167 participants (54%) were found to have high-pain catastrophizing. Age, intent to sue, or number of previous pelvic surgeries did not correlate with high catastrophization. Subjects who catastrophized were significantly more likely to have a higher overall GUPI score (35.0 vs 30.5, P Conclusion Subjects with self-described mesh complications have a high rate of pain catastrophizing associated with significantly worse quality of life and higher pain. Identifying high catastrophizing patients in the setting of chronic pelvic pain from mesh complications may help guide treatment and be an indicator for early or adjunctive psychosocial intervention.

A known side effect of intravesical onabotulinumtoxinA (Botox®) injection for overactive bladder (OAB) is urinary retention requiring clean intermittent catheterization (CIC), the fear of which deters patients from choosing this therapy. In clinical practice, patients with an elevated postvoid residual (PVR) are often managed by observation only, providing they do not have subjective complaints or contraindications. We sought to determine the true rate of urinary retention requiring CIC in clinical practice. A retrospective review was performed over a 3-year period of patients who received 100 units of intravesical onabotulinumtoxinA for the treatment of OAB. Patients were seen 2 weeks after the procedure to measure PVR. CIC was initiated in patients with a PVR ≥350 ml and in those with subjective voiding difficulty or acute retention. A total of 187 injections were performed on 99 female patients. CIC was required following three injections (1.6%): for acute retention in two patients and subjective voiding difficulty in one patient with a PVR of 353 ml. Following 12 injections, the patient had a PVR of ≥350 ml, and following 29 injections, the patient had a PVR of >200 but

INTRODUCTION AND OBJECTIVES:Benign ureteroenteric strictures (UES) may occur after radical cystectomy with urinary diversion. Timely treatment is instrumental in preventing renal insufficiency. The...

Despite routine use of phosphodiesterase type 5 inhibitor to treat erectile dysfunction the role in prostate cancer chemoprevention remains unclear. Only a few studies have explored the link between phosphodiesterase type 5 inhibitor use and prostate cancer. We tested the association between phosphodiesterase type 5 inhibitor and prostate cancer risk in the REDUCE (Reduction by Dutasteride of Prostate Cancer Events) trial.REDUCE was a 4-year multicenter study testing the effect of daily dutasteride on prostate cancer risk in men with prostate specific antigen 2.5 to 10.0 ng/ml and negative biopsy who underwent study mandated biopsies at 2 and 4 years. The association of phosphodiesterase type 5 inhibitor with overall prostate cancer risk and disease grade (Gleason 2-6 and 7-10) was examined using adjusted logistic and multinomial regression analysis. Secondary analysis was performed to explore the association between phosphodiesterase type 5 inhibitor and prostate cancer risk in North American men, given the significantly higher use of phosphodiesterase type 5 inhibitor in these subjects.Phosphodiesterase type 5 inhibitor was not associated with prostate cancer diagnosis (OR 0.90, 95% CI 0.68-1.20, p = 0.476), low grade disease (OR 0.93, 95% CI 0.67-1.27, p = 0.632) or high grade disease (OR 0.85, 95% CI 0.51-1.39, p = 0.508). An inverse trend was seen between phosphodiesterase type 5 inhibitor and prostate cancer diagnosis in North American men but this was not statistically significant (OR 0.67, 95% CI 0.42-1.07, p = 0.091).Phosphodiesterase type 5 inhibitor use was not associated with decreased prostate cancer diagnoses on post-hoc analysis of REDUCE. In North American men, who had much higher baseline use of phosphodiesterase type 5 inhibitor, this treatment was associated with an inverse trend of prostate cancer diagnosis that approached but did not reach statistical significance.

BACKGROUND Uterine power morcellation, where the uterus is shred into smaller pieces, is a widely used technique for removal of uterine specimens in patients undergoing minimally invasive abdominal hysterectomy or myomectomy. Complications related to power morcellation of uterine specimens led to US Food and Drug Administration (FDA) communications in 2014 ultimately recommending against the use of power morcellation for women undergoing minimally invasive hysterectomy. Subsequently, practitioners drastically decreased the use of morcellation. OBJECTIVE We aimed to determine the effect of increased patient awareness on the decrease in use of the morcellator. Google Trends is a public tool that provides data on temporal patterns of search terms, and we correlated this data with the timing of the FDA communication. METHODS Weekly relative search volume (RSV) was obtained from Google Trends using the term “morcellation.” Higher RSV corresponds to increases in weekly search volume. Search volumes were divided into 3 groups: the 2 years prior to the FDA communication, a 1-year period following, and thereafter, with the distribution of the weekly RSV over the 3 periods tested using 1-way analysis of variance. Additionally, we analyzed the total number of websites containing the term “morcellation” over this time. RESULTS The mean RSV prior to the FDA communication was 12.0 (SD 15.8), with the RSV being 60.3 (SD 24.7) in the 1-year after and 19.3 (SD 5.2) thereafter (P CONCLUSIONS Google search activity about morcellation of uterine specimens increased significantly after the FDA communications. This trend indicates an increased public awareness regarding morcellation and its complications. More extensive preoperative counseling and alteration of surgical technique and clinician practice may be necessary.

Background: Uterine power morcellation, where the uterus is shred into smaller pieces, is a widely used technique for removal of uterine specimens in patients undergoing minimally invasive abdominal hysterectomy or myomectomy. Complications related to power morcellation of uterine specimens led to US Food and Drug Administration (FDA) communications in 2014 ultimately recommending against the use of power morcellation for women undergoing minimally invasive hysterectomy. Subsequently, practitioners drastically decreased the use of morcellation. Objective: We aimed to determine the effect of increased patient awareness on the decrease in use of the morcellator. Google Trends is a public tool that provides data on temporal patterns of search terms, and we correlated this data with the timing of the FDA communication. Methods: Weekly relative search volume (RSV) was obtained from Google Trends using the term “morcellation.” Higher RSV corresponds to increases in weekly search volume. Search volumes were divided into 3 groups: the 2 years prior to the FDA communication, a 1-year period following, and thereafter, with the distribution of the weekly RSV over the 3 periods tested using 1-way analysis of variance. Additionally, we analyzed the total number of websites containing the term “morcellation” over this time. Results: The mean RSV prior to the FDA communication was 12.0 (SD 15.8), with the RSV being 60.3 (SD 24.7) in the 1-year after and 19.3 (SD 5.2) thereafter (P

Robotic-assisted sacrocolpopexy (RASC) provides a minimally invasive alternative to the traditional open approach. By taking advantage of both the increased magnification of the laparoscope and precision of the surgical robot, RASC can be safely and efficiently performed. Furthermore, RASC provides the advantages of reduced morbidity with decreased incisional pain and faster return to normal activity.

Groin pain is a challenging clinical problem with a myriad of underlying causes spanning multiple medical specialties. Urological etiologies are often the focus of the diagnostic process; thus, a working knowledge of urological causes is helpful for all specialists who treat groin pain. Although there are multiple identifiable causes of chronic groin pain, often in practice no clear underlying cause is found, and the diagnosis of “chronic pelvic pain syndrome” is given. We still have much to learn about the pathophysiology of chronic groin pain. More robust animal model and clinical studies are needed to develop targeted therapies. In this chapter, we present a review of our current knowledge of how groin pain is classified, evaluated, and managed by urologists. Although complete resolution of chronic pain can be an elusive goal in some patients, effective medical and surgical strategies toward a cure are available for most.

INTRODUCTION AND OBJECTIVES: Robotic surgery has a variable learning curve with multiple factors potentially affecting operative times. We sought to measure the effect of patient, provider, and system-related variables on operative time. METHODS: Retrospective data was collected over a 3.5 year period on 1,099 patients undergoing 11 robotic surgeries by 23 urologists and gynecologists at Cedars-Sinai Medical Center in Los Angeles. Data included patient age, BMI, comorbidities, operative time, surgeon volume, and type of robot (da Vinci Standard vs da Vinci S System). Analyses were performed by linear regression modeling. RESULTS: Average procedure time was 4.87 þ/1.33 hours. Surgeons performed an average of 49 þ/83 surgeries (range 1 to 362, median 1⁄4 8). The upper 25th percentile of surgeons by volume performed 60 or more procedures, and the lower 25th percentile performed four or less. Patients with 25 30) was 0.35 þ/0.08 hours longer vs BMI < 25 (p < 0.001). Diabetes was also associated with increased procedure time, but age and heart disease were not. After performing a subset analysis of surgeons who performed 20 or more surgeries (n 1⁄4 10), the average procedure time for the first 10 surgeries was 4.82 þ/2.83 hours and for the last 10 was 5.03 þ/2.90 hours. The upper (n1⁄45) and lower (n1⁄46) 25th percentile of surgeons had an average procedure time of 5.31 þ/0.74 hours and 4.36 þ/0.77 hours, respectively (p 1⁄4 0.067). After accounting for covariates such as robot type and BMI, high volume surgeons took 0.90 þ/0.44 hours longer than low volume surgeons (p1⁄40.042). The average time for the da Vinci Standard was 4.70 þ/1.12 hours (n1⁄4639 procedures) and for the da Vinci S was 5.10 þ/1.55 hours (n1⁄4493 procedures) (p < 0.001). After accounting for surgeon volume, BMI, department and procedure type, the first generation da Vinci Standard had procedure times 0.35 þ/0.08 hours shorter than the second generation da Vinci S (p < 0.001). CONCLUSIONS: Unexpectedly, surgeon operative times did not tend to improve over time, and operative times were not significantly different between high and low volume surgeons. Also surprisingly operative times were not faster with the newer generation da Vinci model. After overcoming learning curves, surgeons may have an inherent “pace” that dictates their operative time.

514 (82%) patients completed questionnaires. Mean duration of followup questionnaire was 55 months (range 4-173). 193 (37%) patients had at least 5-years follow-up with questionnaire. RESULTS: Prolapse failure occurred in 105/509 (20%) patients at an average of 34 months (range 3-128). 39 (7.6%) patients had cystocele recurrence, 60 (12%) vault prolapse, and 6 (1%) uterine prolapse. 63 (60%) patients chose no intervention. 42 (40%) patients had additional surgery: abdominal sacralcolpopexy (22), transvaginal fascia repair (18), and transvaginal mesh repair (12). 88/514 (17%) patients were sexually active. 25/88 (28%) reported discomfort with intercourse. At the time of each patient’s last questionnaire, 422/514 (82%) patients would recommend surgery and 422/514 (82%) patients would repeat surgery. 311/514 (60%) patients reported satisfaction 8 on a visual analogue scale of 1-10, 10 being extremely satisfied. The complication rate was 4% (19/509) including: small bowel injury during suprapubic tube placement requiring bowel resection (1), infected vaginal hematoma requiring debridement (1), vaginal mesh erosion (2), ureteral obstruction requiring stent (1), vaginal granulation tissue removed in the OR (10), difficulty with intercourse due to vaginal suture which was removed (1), and wound separation treated with estrogen cream (3). CONCLUSIONS: 80% of patients who underwent the CaPS procedure had no significant cystocele recurrence, with average and maximum follow-up exams of 39 months and >13 years, respectively. There was high patient satisfaction and low morbidity.